Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.

Article  PubMed  CAS  Google Scholar 

Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. The Lancet Neurology. Volume 19. Lancet Publishing Group; 2020. pp. 951–62.

Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, et al. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer’s disease. Neuroimage Clin. 2018;19:625–32.

Article  PubMed  PubMed Central  Google Scholar 

Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71(4):266–73.

Article  PubMed  Google Scholar 

Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW, et al. Prevalence and clinical phenotype of Quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77(10):1299–307.

Article  PubMed  PubMed Central  Google Scholar 

Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, et al. The development and convergence of co-pathologies in Alzheimer’s disease. Brain. 2021;144(3):953–62.

Article  PubMed  PubMed Central  Google Scholar 

Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203–12.

Article  PubMed  Google Scholar 

Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021;144(7):2186–98.

Article  PubMed  PubMed Central  Google Scholar 

Levin J, Baiardi S, Quadalti C, Rossi M, Mammana A, Vöglein J, et al. α-Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer’s disease late in the disease course and dependent on Lewy pathology burden. Alzheimer’s & Dementia. 2024;20(6):4351–4365.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA. 2015;313(19):1939.

Article  PubMed  PubMed Central  Google Scholar 

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38.

Article  PubMed  PubMed Central  Google Scholar 

Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med. 2014;6(226):226ra30.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR, Holtzman DM. Biomarker modeling of alzheimer’s disease. Volume 80. Neuron. Cell; 2013. pp. 1347–58.

Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, et al. Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer. Nat Commun. 2022;13(1):6635.

Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer’s disease. Sci Adv. 2020;6(16):eaaz2387.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–49.

Article  PubMed  PubMed Central  Google Scholar 

Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188.

Article  PubMed  Google Scholar 

Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, et al. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain. 2023;146(4):1580–91.

Article  PubMed  Google Scholar 

Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging. 2009;30(12):1895–901.

Article  PubMed  CAS  Google Scholar 

Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p‐tau biomarkers. EMBO Mol Med. 2021;13(8):e14398.

Rabinovici GD, Knopman D, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O et al. Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease: Alzheimer’s Association Workgroup. [cited 2024 May 2]; https://aaic.alz.org/diagnostic-criteria.asp

Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging with [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77(7):829.

Article  PubMed  Google Scholar 

Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561–71.

Article  PubMed  Google Scholar 

Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases. Brain. 2020;143(11):3477–94.

Article  PubMed  PubMed Central  Google Scholar 

Yap SY, Frias B, Wren MC, Schöll M, Fox NC, Årstad E, et al. Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease. Brain. 2021;144(8):2284–90.

Article  PubMed  PubMed Central  Google Scholar 

Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 2016;4(1).

Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA - J Am Med Association. 2018;320(11):1151–62.

Article  CAS  Google Scholar 

Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230–42.

Article  PubMed  PubMed Central  Google Scholar 

Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818–2830.

Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 Tau Positron Emission Tomography in the differentiation of Alzheimer Disease from Other Neurodegenerative disorders. JAMA Neurol. 2020;77(8):955–65.

Article  PubMed  Google Scholar 

Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging. 2021;48(7):2295–305.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–67.

Article  PubMed  PubMed Central  Google Scholar 

Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110–9.

Article  PubMed  Google Scholar 

Macedo AC, Therriault J, Tissot C, Fernandez-Arias J, Ferreira PCL, Vitali P et al. Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging. Brain Commun. 2024;6(2).

Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2021;7(1).

Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601–12.

Article  PubMed  PubMed Central  CAS  Google Scholar 

La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer Disease with the pattern of tau- and Amyloid-PET. Neurology. 2021;96(5):e650–61.

PubMed  PubMed Central  Google Scholar 

Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. The Lancet Neurology. Volume 21. Elsevier Ltd; 2022. pp. 726–34.

Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2097–109.

Article  PubMed  PubMed Central  CAS  Google Scholar 

De Wilde A, Van Der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062–70.

Article  PubMed  PubMed Central